Today
+8.81%
5 Days
+3.82%
1 Month
+18.68%
6 Months
+90.48%
Year to Date
+72.73%
1 Year
+138.18%
• UBS upgraded Illumina to Buy with a price target of $260. • Illumina will rejoin the S&P 500 index from the S&P MidCap 400. • The company reported strong NovaSeq X demand and consecutive earnings beats.
• Stryker's stock declined following an earnings miss and contraction in operating margins. • Management lowered forward-looking guidance due to inflationary pressures and cooling elective procedure demand. • Analysts reduced price targets as automated selling programs accelerated downward stock momentum.


| Shareholders | Proportion |
|---|---|
| Capital World Investors | 13.29% |
| BlackRock Institutional Trust Company, N.A. | 8.69% |
| Vanguard Portfolio Management, LLC | 4.51% |
| Vanguard Capital Management, LLC | 4.36% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 62.42% |
| Investment Advisor/Hedge Fund | 26.92% |
| Hedge Fund | 10.15% |
| Pension Fund | 3.23% |
Related Instruments